Abbreviations GLP-1: Glucagon Like Peptide-1 CV: Cardio Vascular DPP-4: DiPeptidylPeptidase-4 USFDA: United States Food & Drug Administration Aib: 2-Aminoisobutyric acid SNAC: Sodium-N-[8-(2-hydroxybenzoyl)amino]caprylate SUSTAIN: Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes FPG: Fasting Plasma Glucose HOMA-B: Homeostasis model assessment of -cell function ER: Extended release DXA: Dual energy X-ray Absorptiometry OAD: Oral Antidiabetic Drugs SGLT-2: Sodium GLucose co-Transporter-2 SMBG: Self-Monitoring of Blood Glucose PIONEER: Peptide Innovation for Early Diabetes Treatment EMA: European Medicines Agency References Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, DeFronzo RA, Einhorn D, Fonseca VA, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE
M.DeWittD
Circulating adiponectin levels in type 2 diabetes mellitus patients with or without non-alcoholic fatty liver disease: results of a small, open-label, randomized controlled intervention trial in a subgroup receiving short-term exenatide
Victoza (liraglutide), Byetta (exenatide), Bydureon (extended-release exenatide), and Trulicity (dulaglutide) are no longer eligible for weight loss coverage under many Anthem plans
Glucagon-like peptide-1 receptor activation by liraglutide promotes breast cancer through NOX4/ROS/VEGF pathway